Compound Evidence File
#EC-2026-0097
Abaloparatide
Filed under Peptides. The bureau holds 134 laboratory returns for this compound from 48 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
48 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 16 Mar 2026 | 26 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 10.0 | 10.0 | 4 Feb 2026 | 26 Mar 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 7 Apr 2026 | 13 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 10.0 | 10.0 | 9 Apr 2026 | 8 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 10 Mar 2026 | 10 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 22 May 2026 | 14 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 10.0 | 10.0 | 28 Nov 2025 | 20 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Mar 2026 | 1 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Jan 2026 | 19 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 10 Feb 2026 | 25 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Feb 2026 | 27 Apr 2026 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 10.0 | 10.0 | 10.0 | 16 Mar 2025 | 16 Mar 2025 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Mar 2026 | 14 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 9.9 | 11 Feb 2026 | 6 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Jun 2026 | 18 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Jun 2026 | 28 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 14 May 2026 | 22 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 15 May 2026 | 21 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 10.0 | 1 May 2026 | 2 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 21 Feb 2026 | 6 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 9.9 | 18 Mar 2026 | 12 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 5 Jun 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 8.9 | 8.2 | 9.6 | 24 May 2026 | 24 May 2026 |
| Pura PeptidesCASE #VI-2026-0307 | X | 1 | 8.9 | 8.9 | 8.9 | 21 May 2025 | 21 May 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.8 | 7.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.7 | 6.8 | 10.0 | 21 May 2026 | 21 May 2026 |
| UtherCASE #VI-2026-0902 | X | 3 | 8.4 | 7.9 | 9.1 | 25 Apr 2025 | 24 May 2026 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 8.4 | 8.4 | 8.4 | 13 Feb 2025 | 13 Feb 2025 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 8.4 | 8.4 | 8.4 | 7 May 2025 | 7 May 2025 |
| Planet PeptideCASE #VI-2026-0092 | X | 1 | 8.3 | 8.3 | 8.3 | 2 Jul 2025 | 2 Jul 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 7.7 | 6.0 | 9.4 | 24 May 2026 | 24 May 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 7.6 | 7.6 | 7.6 | 16 Mar 2025 | 16 Mar 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 7.4 | 7.4 | 7.4 | 23 May 2026 | 23 May 2026 |
| Top PeptideCASE #VI-2026-0721 | X | 2 | 7.4 | 6.4 | 8.3 | 27 Feb 2025 | 25 May 2026 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 1 | 7.4 | 7.4 | 7.4 | 28 Mar 2025 | 28 Mar 2025 |
| Skye PeptidesCASE #VI-2026-0451 | X | 7 | 7.2 | 5.6 | 10.0 | 9 Jun 2025 | 25 May 2026 |
| Verified PeptidesCASE #VI-2026-0407 | X | 2 | 7.2 | 6.9 | 7.6 | 28 Mar 2025 | 17 May 2026 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 2 | 6.8 | 6.1 | 7.4 | 2 Jul 2025 | 24 May 2026 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 6.3 | 6.3 | 6.3 | 17 Dec 2024 | 17 Dec 2024 |
| Champion PeptideCASE #VI-2026-0909 | X | 1 | 6.1 | 6.1 | 6.1 | 11 Jun 2025 | 11 Jun 2025 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 5.9 | 5.9 | 5.9 | 2 Jul 2025 | 2 Jul 2025 |
| SRY LabsCASE #VI-2026-0657 | X | 2 | 5.3 | 4.3 | 6.3 | 17 Dec 2024 | 24 May 2026 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 3.9 | 3.9 | 3.9 | 14 Jan 2025 | 14 Jan 2025 |
| Changan District Sheng Peptide TradingCASE #VI-2026-0341 | X | 1 | 3.8 | 3.8 | 3.8 | 7 May 2025 | 7 May 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 1.9 | 1.9 | 1.9 | 16 Mar 2025 | 16 Mar 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 21 May 2025 | 21 May 2025 |
Open any subject to view the batch-level evidence for Abaloparatide alone.